Inozyme Pharma (INZY) Short Interest Ratio & Short Volume $4.00 0.00 (0.00%) As of 07/1/2025 Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Inozyme Pharma Short Interest DataInozyme Pharma (INZY) has a short interest of 3.38 million shares, representing 7.79% of the float (the number of shares available for trading by the public). This marks a -8.15% decrease in short interest from the previous month. The short interest ratio (days to cover) is 1.6, indicating that it would take 1.6 days of the average trading volume of 960,267 shares to cover all short positions.Current Short Interest3,380,000 sharesPrevious Short Interest3,680,000 sharesChange Vs. Previous Month-8.15%Dollar Volume Sold Short$13.49 millionShort Interest Ratio1.6 Days to CoverLast Record DateJune 15, 2025Outstanding Shares64,562,000 sharesFloat Size43,370,000 sharesShort Percent of Float7.79%Today's Trading Volume0 sharesAverage Trading Volume960,267 sharesToday's Volume Vs. Average0% Short Selling Inozyme Pharma? Sign up to receive the latest short interest report for Inozyme Pharma and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartINZY Short Interest Over TimeINZY Days to Cover Over TimeINZY Percentage of Float Shorted Over Time Inozyme Pharma Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 6/15/20253,380,000 shares $13.49 million -8.2%7.8%1.6 $3.99 5/31/20253,680,000 shares $14.54 million -4.2%8.5%1.8 $3.95 5/15/20253,840,000 shares $5.45 million -3.8%8.9%2.1 $1.42 4/30/20253,990,000 shares $4.59 million -9.7%9.1%5.7 $1.15 4/15/20254,420,000 shares $4.41 million +5.0%10.2%7.9 $1.00 3/31/20254,210,000 shares $3.83 million +5.5%9.7%6.1 $0.91 3/15/20253,990,000 shares $3.99 million -9.1%9.2%5.8 $1.00 2/28/20254,390,000 shares $5.27 million +2.1%10.1%6 $1.20 2/15/20254,300,000 shares $5.89 million +17.5%9.9%5.4 $1.37 1/31/20253,660,000 shares $5.27 million -4.9%8.3%4.7 $1.44 Get the Latest News and Ratings for INZY and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Inozyme Pharma and its competitors with MarketBeat's FREE daily newsletter. 1/15/20253,850,000 shares $5.31 million +4.1%8.8%5.5 $1.38 12/31/20243,700,000 shares $10.25 million +11.5%8.4%6.8 $2.77 12/15/20243,320,000 shares $10.06 million -2.6%7.6%7 $3.03 11/30/20243,410,000 shares $9.24 million +3.0%7.8%8.4 $2.71 11/15/20243,310,000 shares $10.34 million +2.5%7.6%11.8 $3.13 10/31/20243,230,000 shares $13.86 million +0.6%7.4%12.3 $4.29 10/15/20243,210,000 shares $17.24 million -12.3%7.5%12.7 $5.37 9/30/20243,660,000 shares $19.14 million -6.9%8.6%14.1 $5.23 9/15/20243,930,000 shares $23.58 million -1.3%9.2%13.5 $6.00 8/31/20243,980,000 shares $22.05 million +0.5%9.4%13.2 $5.54 8/15/20243,960,000 shares $18.57 million -4.8%9.4%12.3 $4.69 7/31/20244,160,000 shares $24.13 million -2.4%9.9%13.3 $5.80 7/15/20244,260,000 shares $23.26 million +3.2%10.2%11.5 $5.46 6/30/20244,130,000 shares $18.42 million +51.3%9.9%8.8 $4.46 6/15/20242,730,000 shares $12.94 million +0.4%6.6%4.8 $4.74 5/31/20242,720,000 shares $13.11 million +1.1%6.5%4.5 $4.82 5/15/20242,690,000 shares $12.56 million -20.7%6.5%4.1 $4.67 4/30/20243,390,000 shares $14.95 million +7.6%8.2%5 $4.41 4/15/20243,150,000 shares $14.84 million +22.1%7.7%4.7 $4.71 3/31/20242,580,000 shares $19.76 million +8.4%6.3%4.2 $7.66 3/15/20242,380,000 shares $14.02 million +2.6%5.8%4.6 $5.89 2/29/20242,320,000 shares $14.76 million -3.3%5.6%4.8 $6.36 2/15/20242,400,000 shares $13.70 million -16.4%5.8%5.4 $5.71 1/31/20242,870,000 shares $15.79 million +4.7%6.8%6.9 $5.50 1/15/20242,740,000 shares $11.54 million -10.8%6.5%6.7 $4.21 12/31/20233,070,000 shares $13.08 million +91.9%7.2%7.6 $4.26 12/15/20231,600,000 shares $6.43 million -28.6%3.8%3.7 $4.02 11/30/20232,240,000 shares $8.62 million -0.4%5.3%4.5 $3.85 11/15/20232,250,000 shares $7.20 million +8.2%5.3%4.2 $3.20 10/31/20232,080,000 shares $6.18 million -15.5%4.7%3.6 $2.97HIDDEN IN THE BOOK OF GENESIS… (Ad)“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.Watch Jim Rickards reveal the Old Testament Wealth Code 10/15/20232,460,000 shares $8.35 million +6.5%5.5%3.7 $3.40 9/30/20232,310,000 shares $9.70 million +12.7%5.2%3.3 $4.20 9/15/20232,050,000 shares $8.82 million +21.3%4.6%3 $4.30 8/31/20231,690,000 shares $8.28 million -17.2%4.5%2.6 $4.90 8/15/20232,040,000 shares $9.83 million +11.5%5.4%3.3 $4.82 7/31/20231,830,000 shares $9.33 million +7.7%4.0%2.8 $5.10 7/15/20231,700,000 shares $10.35 million +37.1%4.9%3.1 $6.09 6/30/20231,240,000 shares $6.91 million +248.1%3.5%2 $5.57 6/15/2023356,200 shares $2.07 million +24.9%1.0%0.5 $5.81 5/31/2023285,100 shares $1.71 million -53.0%0.8%0.4 $5.99 5/15/2023606,300 shares $3.93 million No Change1.7%0.7 $6.49 10/31/2022166,500 shares $293.04 thousand -4.8%N/A2.3 $1.76 10/15/2022174,800 shares $457.98 thousand -4.4%N/A2.9 $2.62 9/30/2022182,900 shares $490.17 thousand No ChangeN/A2.4 $2.68 9/15/2022182,900 shares $610.89 thousand -7.6%0.8%1.5 $3.34 8/31/2022197,900 shares $593.70 thousand -25.9%0.9%1.2 $3.00 8/15/2022267,000 shares $1.00 million -18.8%1.2%1.5 $3.76 7/31/2022328,800 shares $1.21 million -26.3%N/A1.7 $3.69 7/15/2022446,200 shares $2.23 million -47.1%N/A1.8 $5.00 6/30/2022842,900 shares $4.02 million -2.5%N/A2.8 $4.77 6/15/2022864,400 shares $4.02 million +0.3%N/A2.8 $4.65 5/31/2022861,600 shares $3.18 million +13.8%N/A3.5 $3.69 5/15/2022757,200 shares $3.20 million -13.6%N/A3.4 $4.23 4/30/2022876,200 shares $3.46 million +118.3%N/A4.2 $3.95 4/15/2022401,300 shares $1.71 million +23.5%1.7%2.3 $4.26 3/31/2022325,000 shares $1.33 million +12.2%N/A3.7 $4.09 3/15/2022289,700 shares $1.17 million -3.9%2.1%4.4 $4.03 2/28/2022301,300 shares $1.74 million +9.7%2.2%4.5 $5.77 2/15/2022274,700 shares $1.95 million +5.2%2.4%4.3 $7.10 1/31/2022261,200 shares $1.74 million +57.7%2.2%4.6 $6.68 1/15/2022165,600 shares $1.12 million +8.2%N/A3.1 $6.74 12/31/2021153,000 shares $1.04 million -13.6%1.3%2.9 $6.82 12/15/2021177,000 shares $987.66 thousand -3.2%1.5%2.8 $5.58 11/30/2021182,800 shares $1.45 million +4.1%1.6%2.4 $7.94 11/15/2021175,600 shares $1.76 million -7.1%1.5%2.1 $10.00 10/29/2021189,100 shares $1.77 million -3.2%1.7%2.3 $9.34 10/15/2021195,400 shares $1.81 million -14.2%1.8%2.2 $9.25 9/30/2021227,800 shares $2.64 million +11.5%2.1%2.5 $11.59 9/15/2021204,300 shares $2.56 million -43.5%1.9%2.4 $12.55 8/31/2021361,500 shares $5.57 million -5.9%3.3%5.2 $15.42 8/13/2021384,100 shares $6.10 million +3.4%3.5%6.3 $15.88 7/30/2021371,400 shares $6.23 million +32.0%3.4%5.9 $16.77 7/15/2021281,300 shares $5.12 million -78.4%2.8%4.8 $18.19 6/30/20211,300,000 shares $22.15 million +26.2%12.7%24.2 $17.04 6/15/20211,030,000 shares $17.64 million +15.4%10.1%21.5 $17.13 5/28/2021892,200 shares $14.60 million +2.4%8.7%19.7 $16.36 5/14/2021871,000 shares $13.23 million -39.5%8.5%18.3 $15.19 4/30/20211,440,000 shares $26.40 million +0.7%14.1%27.8 $18.33 4/15/20211,430,000 shares $27.01 million +8.3%N/A22.9 $18.89 3/31/20211,320,000 shares $24.20 million +20.0%16.3%20.6 $18.33HIDDEN IN THE BOOK OF GENESIS… (Ad)“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.Watch Jim Rickards reveal the Old Testament Wealth Code 3/15/20211,100,000 shares $23.38 million No Change14.9%16.4 $21.25 2/26/20211,100,000 shares $22.98 million +8.9%14.9%18.6 $20.89 2/12/20211,010,000 shares $20.16 million +85.0%13.7%17.7 $19.96 1/29/2021546,000 shares $12.49 million +1.8%7.4%9.8 $22.88 1/15/2021536,300 shares $14.19 million No Change7.7%13.5 $26.45 INZY Short Interest - Frequently Asked Questions What is Inozyme Pharma's current short interest? Short interest is the volume of Inozyme Pharma shares that have been sold short but have not yet been closed out or covered. As of June 15th, investors have sold 3,380,000 shares of INZY short. 7.79% of Inozyme Pharma's shares are currently sold short. Learn More on Inozyme Pharma's current short interest. What is a good short interest ratio for Inozyme Pharma? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. INZY shares currently have a short interest ratio of 2.0. Learn More on Inozyme Pharma's short interest ratio. What is a good short interest percentage for Inozyme Pharma? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 7.79% of Inozyme Pharma's floating shares are currently sold short. Is Inozyme Pharma's short interest increasing or decreasing? Inozyme Pharma saw a drop in short interest in the month of June. As of June 15th, there was short interest totaling 3,380,000 shares, a drop of 8.2% from the previous total of 3,680,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Inozyme Pharma's float size? Inozyme Pharma currently has issued a total of 64,562,000 shares. Some of Inozyme Pharma's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Inozyme Pharma currently has a public float of 43,370,000 shares. How does Inozyme Pharma's short interest compare to its competitors? 7.79% of Inozyme Pharma's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Inozyme Pharma: Dyne Therapeutics, Inc. (16.77%), Akebia Therapeutics, Inc. (10.01%), Collegium Pharmaceutical, Inc. (14.13%), Zymeworks Inc. (3.24%), Spyre Therapeutics, Inc. (26.29%), Verve Therapeutics, Inc. (9.36%), Amphastar Pharmaceuticals, Inc. (11.74%), Arcus Biosciences, Inc. (17.20%), LENZ Therapeutics, Inc. (16.33%), Oric Pharmaceuticals, Inc. (15.84%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($69.26 billion), Invesco QQQ ($25.22 billion), iShares Russell 2000 ETF ($20.33 billion), iShares 20+ Year Treasury Bond ETF ($9.99 billion), MicroStrategy Incorporated ($9.12 billion), Canadian Natural Resources Limited ($6.73 billion), SPDR S&P Biotech ETF ($6.52 billion), Invesco S&P 500 Equal Weight ETF ($5.60 billion), Financial Select Sector SPDR Fund ($4.64 billion), and iShares iBoxx $ Investment Grade Corporate Bond ETF ($4.59 billion). View all of the most shorted stocks. What does it mean to sell short Inozyme Pharma stock? Short selling INZY is an investing strategy that aims to generate trading profit from Inozyme Pharma as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Inozyme Pharma? A short squeeze for Inozyme Pharma occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of INZY, which in turn drives the price of the stock up even further. How often is Inozyme Pharma's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including INZY, twice per month. The most recent reporting period available is June, 15 2025. More Short Interest Resources from MarketBeat Related Companies DYN Short Interest Data AKBA Short Interest Data COLL Short Interest Data ZYME Short Interest Data SYRE Short Interest Data VERV Short Interest Data AMPH Short Interest Data RCUS Short Interest Data LENZ Short Interest Data ORIC Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:INZY) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredThis New Rule Could Change EverythingA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredBitcoin just humbled Jeff BezosBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inozyme Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inozyme Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
